 | • レポートコード：GIR201114934 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、一次進行型多発性硬化症治療の世界市場を調査対象にし、一次進行型多発性硬化症治療の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他）、用途別分析（病院、クリニック、その他）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：F. Hoffmann-La Roche Ltd.、Kyorin Pharmaceutical Co., Ltd.、Genzyme Corporation、Teva Pharmaceutical Industries Ltd.、Glialogix, Inc.、Santhera Pharmaceuticals Holding AG、MedDay SA ・企業別売上、市場シェア ・一次進行型多発性硬化症治療の地域別市場分析 ・一次進行型多発性硬化症治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・一次進行型多発性硬化症治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・一次進行型多発性硬化症治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・一次進行型多発性硬化症治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・一次進行型多発性硬化症治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・一次進行型多発性硬化症治療の種類別市場規模2015-2020：ApE、ビオチン、GZ-402668、イブジラスト、イデベノン、ラキニモドナトリウム、その他 ・一次進行型多発性硬化症治療の用途別市場規模2015-2020：病院、クリニック、その他 ・一次進行型多発性硬化症治療の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論 |
Market Overview
The global Primary Progressive Multiple Sclerosis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Primary Progressive Multiple Sclerosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Primary Progressive Multiple Sclerosis Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Primary Progressive Multiple Sclerosis Treatment market has been segmented into:
ApE
Biotin
GZ-402668
Ibudilast
Idebenone
Laquinimod Sodium
Others
By Application, Primary Progressive Multiple Sclerosis Treatment has been segmented into:
Hospital
Clinic
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Primary Progressive Multiple Sclerosis Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Primary Progressive Multiple Sclerosis Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Primary Progressive Multiple Sclerosis Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Primary Progressive Multiple Sclerosis Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Primary Progressive Multiple Sclerosis Treatment Market Share Analysis
Primary Progressive Multiple Sclerosis Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Primary Progressive Multiple Sclerosis Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Primary Progressive Multiple Sclerosis Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Primary Progressive Multiple Sclerosis Treatment are:
F. Hoffmann-La Roche Ltd.
Kyorin Pharmaceutical Co., Ltd.
Genzyme Corporation
Teva Pharmaceutical Industries Ltd.
Glialogix, Inc.
Santhera Pharmaceuticals Holding AG
MedDay SA
Table of Contents
1 Primary Progressive Multiple Sclerosis Treatment Market Overview
1.1 Product Overview and Scope of Primary Progressive Multiple Sclerosis Treatment
1.2 Classification of Primary Progressive Multiple Sclerosis Treatment by Type
1.2.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type in 2019
1.2.3 ApE
1.2.4 Biotin
1.2.5 GZ-402668
1.2.6 Ibudilast
1.2.7 Idebenone
1.2.8 Laquinimod Sodium
1.2.9 Others
1.3 Global Primary Progressive Multiple Sclerosis Treatment Market by Application
1.3.1 Overview: Global Primary Progressive Multiple Sclerosis Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Primary Progressive Multiple Sclerosis Treatment Market by Regions
1.4.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Primary Progressive Multiple Sclerosis Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Primary Progressive Multiple Sclerosis Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Primary Progressive Multiple Sclerosis Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Primary Progressive Multiple Sclerosis Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Primary Progressive Multiple Sclerosis Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Primary Progressive Multiple Sclerosis Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 F. Hoffmann-La Roche Ltd.
2.1.1 F. Hoffmann-La Roche Ltd. Details
2.1.2 F. Hoffmann-La Roche Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 F. Hoffmann-La Roche Ltd. SWOT Analysis
2.1.4 F. Hoffmann-La Roche Ltd. Product and Services
2.1.5 F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Kyorin Pharmaceutical Co., Ltd.
2.2.1 Kyorin Pharmaceutical Co., Ltd. Details
2.2.2 Kyorin Pharmaceutical Co., Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Kyorin Pharmaceutical Co., Ltd. SWOT Analysis
2.2.4 Kyorin Pharmaceutical Co., Ltd. Product and Services
2.2.5 Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Genzyme Corporation
2.3.1 Genzyme Corporation Details
2.3.2 Genzyme Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Genzyme Corporation SWOT Analysis
2.3.4 Genzyme Corporation Product and Services
2.3.5 Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Teva Pharmaceutical Industries Ltd.
2.4.1 Teva Pharmaceutical Industries Ltd. Details
2.4.2 Teva Pharmaceutical Industries Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Teva Pharmaceutical Industries Ltd. SWOT Analysis
2.4.4 Teva Pharmaceutical Industries Ltd. Product and Services
2.4.5 Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Glialogix, Inc.
2.5.1 Glialogix, Inc. Details
2.5.2 Glialogix, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Glialogix, Inc. SWOT Analysis
2.5.4 Glialogix, Inc. Product and Services
2.5.5 Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Santhera Pharmaceuticals Holding AG
2.6.1 Santhera Pharmaceuticals Holding AG Details
2.6.2 Santhera Pharmaceuticals Holding AG Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Santhera Pharmaceuticals Holding AG SWOT Analysis
2.6.4 Santhera Pharmaceuticals Holding AG Product and Services
2.6.5 Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 MedDay SA
2.7.1 MedDay SA Details
2.7.2 MedDay SA Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 MedDay SA SWOT Analysis
2.7.4 MedDay SA Product and Services
2.7.5 MedDay SA Primary Progressive Multiple Sclerosis Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Primary Progressive Multiple Sclerosis Treatment Players Market Share
3.2.2 Top 10 Primary Progressive Multiple Sclerosis Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue and Market Share by Regions
4.2 North America Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
5 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
5.1 North America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
5.2 USA Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
6 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
6.1 Europe Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
6.2 Germany Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
6.4 France Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
7.1 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
7.2 China Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
7.5 India Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
8 South America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries
8.1 South America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
8.2 Brazil Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Primary Progressive Multiple Sclerosis Treatment by Countries
9.1 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Primary Progressive Multiple Sclerosis Treatment Market Forecast by Type (2019-2024)
10.3 ApE Revenue Growth Rate (2015-2025)
10.4 Biotin Revenue Growth Rate (2015-2025)
10.5 GZ-402668 Revenue Growth Rate (2015-2025)
10.6 Ibudilast Revenue Growth Rate (2015-2025)
10.7 Idebenone Revenue Growth Rate (2015-2025)
10.8 Laquinimod Sodium Revenue Growth Rate (2015-2025)
10.9 Others Revenue Growth Rate (2015-2025)
11 Global Primary Progressive Multiple Sclerosis Treatment Market Segment by Application
11.1 Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application (2015-2020)
11.2 Primary Progressive Multiple Sclerosis Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Clinic Revenue Growth (2015-2020)
11.5 Others Revenue Growth (2015-2020)
12 Global Primary Progressive Multiple Sclerosis Treatment Market Size Forecast (2021-2025)
12.1 Global Primary Progressive Multiple Sclerosis Treatment Market Size Forecast (2021-2025)
12.2 Global Primary Progressive Multiple Sclerosis Treatment Market Forecast by Regions (2021-2025)
12.3 North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
12.6 South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Primary Progressive Multiple Sclerosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. F. Hoffmann-La Roche Ltd. Corporate Information, Location and Competitors
Table 6. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Major Business
Table 7. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 8. F. Hoffmann-La Roche Ltd. SWOT Analysis
Table 9. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 10. F. Hoffmann-La Roche Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Kyorin Pharmaceutical Co., Ltd. Corporate Information, Location and Competitors
Table 12. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Major Business
Table 13. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Kyorin Pharmaceutical Co., Ltd. SWOT Analysis
Table 15. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 16. Kyorin Pharmaceutical Co., Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Genzyme Corporation Corporate Information, Location and Competitors
Table 18. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Major Business
Table 19. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Genzyme Corporation SWOT Analysis
Table 21. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 22. Genzyme Corporation Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Teva Pharmaceutical Industries Ltd. Corporate Information, Location and Competitors
Table 24. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Major Business
Table 25. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Teva Pharmaceutical Industries Ltd. SWOT Analysis
Table 27. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 28. Teva Pharmaceutical Industries Ltd. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Glialogix, Inc. Corporate Information, Location and Competitors
Table 30. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Major Business
Table 31. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Glialogix, Inc. SWOT Analysis
Table 33. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 34. Glialogix, Inc. Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Santhera Pharmaceuticals Holding AG Corporate Information, Location and Competitors
Table 36. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Major Business
Table 37. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Santhera Pharmaceuticals Holding AG SWOT Analysis
Table 39. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 40. Santhera Pharmaceuticals Holding AG Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. MedDay SA Corporate Information, Location and Competitors
Table 42. MedDay SA Primary Progressive Multiple Sclerosis Treatment Major Business
Table 43. MedDay SA Primary Progressive Multiple Sclerosis Treatment Total Revenue (USD Million) (2017-2018)
Table 44. MedDay SA SWOT Analysis
Table 45. MedDay SA Primary Progressive Multiple Sclerosis Treatment Product and Solutions
Table 46. MedDay SA Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Players (2015-2020)
Table 48. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Players (2015-2020)
Table 49. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Regions (2015-2020)
Table 50. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Regions (2015-2020)
Table 51. North America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
Table 52. North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Table 53. Europe Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 54. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 55. South America Primary Progressive Multiple Sclerosis Treatment Revenue by Countries (2015-2020)
Table 56. South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Table 57. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Countries (2015-2020)
Table 58. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Table 59. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) by Type (2015-2020)
Table 60. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Type (2015-2020)
Table 61. Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Type (2021-2025)
Table 62. Global Primary Progressive Multiple Sclerosis Treatment Revenue by Application (2015-2020)
Table 63. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Application (2015-2020)
Table 64. Global Primary Progressive Multiple Sclerosis Treatment Revenue Forecast by Application (2021-2025)
Table 65. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Primary Progressive Multiple Sclerosis Treatment Picture
Figure 2. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Type in 2019
Figure 3. ApE Picture
Figure 4. Biotin Picture
Figure 5. GZ-402668 Picture
Figure 6. Ibudilast Picture
Figure 7. Idebenone Picture
Figure 8. Laquinimod Sodium Picture
Figure 9. Others Picture
Figure 10. Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Application in 2019
Figure 11. Hospital Picture
Figure 12. Clinic Picture
Figure 13. Others Picture
Figure 14. Global Primary Progressive Multiple Sclerosis Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Primary Progressive Multiple Sclerosis Treatment Revenue Market Share in 2019
Figure 23. Global Top 10 Players Primary Progressive Multiple Sclerosis Treatment Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Regions (2015-2020)
Figure 27. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Regions in 2018
Figure 28. North America Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 29. Europe Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 31. South America Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 33. North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 34. North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries in 2019
Figure 35. USA Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Canada Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 38. Europe Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries in 2019
Figure 40. Germany Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 41. UK Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 42. France Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Russia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Italy Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries in 2019
Figure 47. China Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 48. Japan Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Korea Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 50. India Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 52. South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 53. South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries in 2019
Figure 54. Brazil Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 59. UAE Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Primary Progressive Multiple Sclerosis Treatment Revenue and Growth Rate (2015-2020)
Figure 62. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Type (2015-2020)
Figure 63. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Type in 2019
Figure 64. Global Primary Progressive Multiple Sclerosis Treatment Market Share Forecast by Type (2021-2025)
Figure 65. Global ApE Revenue Growth Rate (2015-2020)
Figure 66. Global Biotin Revenue Growth Rate (2015-2020)
Figure 67. Global GZ-402668 Revenue Growth Rate (2015-2020)
Figure 68. Global Ibudilast Revenue Growth Rate (2015-2020)
Figure 69. Global Idebenone Revenue Growth Rate (2015-2020)
Figure 70. Global Laquinimod Sodium Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Application (2015-2020)
Figure 73. Global Primary Progressive Multiple Sclerosis Treatment Revenue Share by Application in 2019
Figure 74. Global Primary Progressive Multiple Sclerosis Treatment Market Share Forecast by Application (2021-2025)
Figure 75. Global Hospital Revenue Growth Rate (2015-2020)
Figure 76. Global Clinic Revenue Growth Rate (2015-2020)
Figure 77. Global Others Revenue Growth Rate (2015-2020)
Figure 78. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Primary Progressive Multiple Sclerosis Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Primary Progressive Multiple Sclerosis Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
Figure 82. Europe Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
Figure 84. South America Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Primary Progressive Multiple Sclerosis Treatment Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
進行性再発型多発性硬化症（RMS）治療の世界市場 2020年 Market Overview The global Progressive Relapsing Multiple Sclerosis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019…- 二次進行型多発性硬化症治療薬の世界市場 2020年 Market Overview The global Secondary Progressive Multiple Sclerosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The…
- 多発性内分泌腫瘍治療の世界市場 2020年 Market Overview The global Multiple Endocrine Neoplasia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Multip…
- 全身性硬化症治療の世界市場 2020年 Market Overview The global Systemic Sclerosis Treatments market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Systemic Sclero…
- 進行性多巣性白質脳症（PML）治療薬の世界市場 2020年 Market Overview The global Progressive Multifocal Leukoencephalopathy Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. T…